MedPath

DOF INC.

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction

Recruiting
Conditions
Breast Reconstruction
Breast Cancer Female
First Posted Date
2024-08-15
Last Posted Date
2024-08-15
Lead Sponsor
DOF Inc.
Target Recruit Count
120
Registration Number
NCT06555614
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Evaluation of the Clinical Effectiveness and Safety of Acellular Dermal Matrix(SC DERM® Recon) in Breast Reconstruction

Recruiting
Conditions
Breast Cancer Female
Breast Reconstruction
First Posted Date
2024-08-15
Last Posted Date
2024-08-15
Lead Sponsor
DOF Inc.
Target Recruit Count
120
Registration Number
NCT06555692
Locations
🇰🇷

Soon Chun Hyang University Hospital, Seoul, Korea, Republic of

Evaluation of ADM(SC Derm® Recon) in Breast Reconstruction

Recruiting
Conditions
Breast Cancer Female
First Posted Date
2024-08-14
Last Posted Date
2024-08-14
Lead Sponsor
DOF Inc.
Target Recruit Count
100
Registration Number
NCT06553859
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.